PBE ETF (Invesco Biotechnology and Genome ETF) is managed by Invesco (US) with $261.9M in net assets. PBE expense ratio is 0.58%, holding 33 positions across sectors including Health Care, Financials, Unknown. Inception date: 2005-06-23.

PBE performance shows a YTD return of 2.90%. The 1-year return is 35.13% and the 5-year return is 2.98%. PBE dividend yield stands at 1.03%, paid quarterly.

PBE top holdings include United Therapeutics Corp (6.5%), Illumina, Inc. (5.2%), Regeneron Pharmaceuticals, Inc. (5.2%), Alnylam Pharmaceuticals Inc. (5.2%), Gilead Sciences Inc (4.9%). View all PBE holdings, sector breakdown, or dividend history.

PBE can be compared against other funds using the overlap calculator or side-by-side comparison tool. PBE alternatives are available via the screener, along with tax-loss harvesting opportunities.